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Purpose: The improvement of available endovascular aortic aneurysm repair (EVAR) devices is critical for the advancement
of patient care in vascular surgery. The goal of this article is to report a highly detailed, closely monitored, audited, pooled
multicenter cohort of open surgical abdominal aortic aneurysm (AAA) repairs that has potential for use in future EVAR
studies as a control data set.
Methods: Open surgical AAA repair data from four investigational device exemption clinical aortic endograft trials were
tested for poolability, merged, and analyzed for the intervals of 0 to 30 days and 31 to 365 days.
Results: The data set includes 323 open patients (83% men; mean age, 70 years). Operative mortality at 30 days was 2.8%.
The mean age of women was 3 years older than men, and mortality at 30 days for women was 5.7% compared with 2.2%
for men (P  .18). Operative mortality for patients with large AAAs (>5.5 cm, 3.6%) was not different than for patients
with small aneurysms (<5.5 cm, 2.4%, P  .54). All-cause mortality at 1 year was 6.7%, with significant predictors
including age, sex, and renal failure. Women had 2.6-fold greater 1-year all-cause mortality rate (13.2%) than men (5.4%,
P  .04), but statistical significance was lost after correction for age. Two additional AAA-related deaths occurred
between days 31 and 365, resulting in a 1-year AAA-related mortality of 3.5%.
Conclusion: This data set provides a tightly controlled, thoroughly detailed, and audited experience that has the potential
to serve as an open control group for future EVAR trials. ( J Vasc Surg 2008;48:511-8.)Open surgical repair of infrarenal abdominal aortic
aneurysms (AAA) in patients judged to be acceptable can-
didates for open surgery has been shown safe and effective.
Huber et al1 reported a 4.2% rate of in-hospital mortality
according to an analysis of the Nationwide Inpatient Sam-
ple (NIS), representing 20% of all patients in nonfederal
United States (US) hospitals during 1994 to 1996. Analysis
of the New York State discharge data set revealed a 3.55%
in-hospital mortality rate in all patients who underwent
surgical repair during 2001, and Schermerhorn et al2 iden-
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beneficiaries who underwent open surgical repair between
2001 and 2004.3
The development of commercially approved endovas-
cular AAA grafts in the United States entailed the perfor-
mance of controlled investigational device exemption
(IDE) clinical trials, sponsored by device manufacturers
and reported previously.4-8 The Society for Vascular Sur-
gery (SVS) established the Lifeline Registry for Endovascu-
lar Aneurysm Repair (EVAR) to assess long-term EVAR
outcomes using a standardized format to pool data from
controlled IDE clinical trials sponsored by device manufac-
turers.9-11 In these reports, safety was represented as an
assessment of both morbidity and mortality of the proce-
dure through 30 days and 12 months of follow-up. Addi-
tional efficacy end points, largely specific to endovascular
repair, were established to ensure that the device met the
intended treatment goals.
Because EVAR has a lower operative mortality than
surgical repair, EVAR has become a common—if not the
prevalent—treatment for elective AAA repair.12 Patients
who currently undergo open surgical repair may do so
because they are not candidates for EVAR due to an insuf-
ficient infrarenal aortic neck length or other anatomic lim-
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repair, and given the potential confounder that the com-
plexity of surgical repair could be perturbed by anatomic
features such as a short infrarenal neck, it has become
increasingly difficult for manufacturers of EVAR grafts to
establish an acceptable open surgical control group for
concomitant comparisons of new endovascular aortic de-
vices.
This report offers a potential solution, with publication
of pooled open surgical AAA repair data from four IDE
EVAR trials. The detailed data derived from this group of
surgical controls may be one of the last data sets that
includes prospectively collected, highly detailed, con-
trolled, and audited information derived from surgical re-
pair patients before extensive proliferation of EVAR; there-
fore, the SVS Outcomes Committee undertook the
following analysis of the open surgical control cohort.
METHODS
The SVS Outcomes Committee approached all manu-
facturers who conducted clinical trials to gain premarket
US Food and Drug Administration (FDA) approval for
EVAR intended for the treatment of infrarenal aortic aneu-
rysms using concurrent enrollment of surgical controls.
Four manufacturers agreed to share their IDE clinical data
relating to the surgical control cohort. These data sets were
pooled into a registry managed by New England Research
Institutes Inc (NERI, Watertown, Mass). Oversight of the
project was provided by the SVS Outcomes Committee. A
common aggregate database was created from data re-
ceived as SAS data sets (SAS Institute, Cary, NC) or Excel
spreadsheets (Microsoft Corp, Redmond, Wash).
The primary outcome measures for the surgical control
cohort are (1) operative mortality, defined as death during
the initial hospitalization or death from any cause30 days
of the primary procedure; (2) aneurysm-related mortality,
defined as death from any cause 30 days of the primary
procedure or death30 days of a secondary procedure; (3)
all-cause mortality; (4) serious morbidity; and (5) major
adverse events (MAEs).
Although all adverse events were documented within
the data set, serious morbidity included adverse events that
met one or more of the following criteria: fatal, immedi-
ately life-threatening, requiring or prolonging inpatient
hospitalization (includes readmission), or results in persis-
tent or significant disability or incapacity. In addition,
MAEs are defined as any of the following events: death,
stroke (excludes transient ischemic attack), myocardial in-
farction, renal failure (excludes renal insufficiency), respira-
tory failure (excludes chronic obstructive pulmonary dis-
ease or pulmonary complications), and paralysis (excludes
paraparesis). End points were analyzed in the context of the
entire aggregate data set, as well as specific to gender and
aneurysm size (5.5 cm vs 5.5 cm) and other preopera-
tive variables. Secondary end points included surgery dura-
tion, hours in the intensive care unit, and hospital length of
stay.Statistical methods. To determine the poolability of
subjects among protocols, the inclusion and exclusion cri-
teria used to determine eligibility of surgical controls, as
available for each protocol, were reviewed. A comparison
wasmade among themanufacturers on all available baseline
characteristics for the patients, including demographics,
medical history, and preoperative AAA diameter. Tests of
statistical significance were conducted with 2 or Fisher
exact tests for categoric variables and analysis of variance for
continuous variables. Multiple comparison t tests, with a
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Fig 1. Preoperative aneurysm diameter distribution of patients
undergoing open surgical repair. The preoperative aneurysm di-
ameter measurement was missing for 31 patients.
Table I. Demographics and comorbidities of the open
repair surgical control patients
Variable Percentage or mean  SD (range)
Total patients, No. 323
Age, years 70.1  7.4 (41-86)
Gender, male 83.3 (269/323)
Race, white 94.9 (244/257)
Coronary artery disease 53.3 (172/323)
Myocardial infarction 32.8 (106/323)
Arrhythmia 13.9 (45/323)
Peripheral vascular disease 18.0 (58/323)
Valvular heart disease 8.5 (15/177)
Congestive heart failure 6.5 (21/323)
Hypertension 70.6 (228/323)
Cerebrovascular disease 13.6 (44/323)
Thromboembolic event 5.5 (14/257)
Liver disease 3.4 (5/146)
COPD 26.9 (87/323)
Diabetes 12.7 (41/323)
Renal failurea 3.1 (10/323)
Cancer 23.6 (50/212)
Family history of AAA disease 17.9 (38/212)
Smoking 88.2 (285/323)
Alcohol 8.5 (18/212)
Pre-op AAA size 58.7  11.9 (31-100)
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary
disease; SD, standard deviation.
aDefined as creatinine 3.0 mg/dL.Bonferroni adjustment, were used to compare preoperative
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ufacturers, the surgical control data were also compared
with each manufacturer’s summary of safety and effective-
ness (SSED) to ensure the data received was complete and
calculated accurately.
Descriptive statistics are listed as mean  standard
deviation for continuous variables and number (percent-
age) for categoric variables. Subset analyses were performed
using the two-tailed t test for continuous variables and the
2 or Fisher exact, as necessary, for discrete/categoric data.
Kaplan-Meier estimates, using the log-rank test, were used
to compare the primary outcome between groups for free-
dom from death (ie, survival), aneurysm-related death,
serious morbidity, and major adverse events. Differences
were considered significant if P  .05. Cox proportional
hazards models were performed to assess predictive factors
Fig 2. Freedom from all-cause mortality in patients undergoing
open surgical repair.
Fig 3. Freedom from aneurysm-related mortality in patients un-
dergoing open surgical repair.of outcome (ie, potential independent risk factors). Allstatistical analyses were performed by NERI using SAS
statistical software.
RESULTS
Patient population. Open surgical control patients
(269men and 54women) from four IDE clinical trials were
pooled and analyzed. Baseline demographic information
and comorbid factors are reported in in Table I. Average
age was 70 years, with 23% aged 65 years and 7% aged
80 years, and 95% were white. The average preoperative
aneurysm diameter was 5.9 1.2 cm (range, 3.1-10.0 cm),
with size distribution as detailed in Fig 1. Demographic
characteristics were similar among the IDE trials with the
following exceptions:
● One manufacturer had more patients with a history of
smoking than the other three manufacturers.
● More patients with a history of arrhythmia were
present in two of the trials compared with the others.
● More patients with peripheral vascular disease were
Table II. Secondary outcome measures
Outcome Mean  SD (range)
Duration of surgery, mina 195.7  82.3 (57-498)
Hours in ICUb 77.1  165.4 (0-1728)
Days to hospital dischargec 8.3  7.4 (0-72)
ICU, Intensive care unit; SD, standard deviation.
aOnly available on 240 patients.
bOnly available on 315 patients.
cOnly available on 301 patients.
Table III. Cox proportional hazard for aneurysm-related
mortality and all-cause mortality at 1-year: analysis of
maximum likelihood estimates
Variable HR 95% HR CL P
Aneurysm-related mortality
Age 1.085 0.991 1.188 .0786
Female 4.237 1.292 13.889 .0171
Myocardial infarction 3.766 1.102 12.868 .0344
Hypertension 1.903 0.411 8.809 .4104
COPD 0.612 0.132 2.835 .5305
Diabetes mellitus 0.681 0.087 5.318 .7139
Renal failure 3.368 0.431 26.334 .2471
Aneurysm size 1.013 0.968 1.061 .5739
All-cause mortality
Age 1.098 1.027 1.174 .0062
Female 2.632 1.062 6.536 .0368
Myocardial infarction 1.655 0.697 3.929 .2531
Congestive heart failure 1.598 0.372 6.860 .5286
Hypertension 1.825 0.614 5.424 .2790
COPD 1.104 0.428 2.846 .8372
Diabetes mellitus 1.152 0.339 3.910 .8208
Renal failure 6.169 1.815 20.972 .0036
Aneurysm size 1.003 0.968 1.040 .8498
CL, Confidence limits; COPD, chronic obstructive pulmonary disease;HR,
hazard ratio.found in two trials.
astroin
upper
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with a history of hypertension between manufacturers.
● Preoperative AAA diameter was larger in onemanufac-
turer’s cohort compared with the others.
Arrhythmia, peripheral vascular disease, hypertension,
smoking, and AAA diameter do not appear to have an effect
on outcome when adjusting for manufacturer.
Primary and secondary outcome measures. The 30-
day and in-hospital mortality rate was 2.8% (9 deaths,
Fig 2). Two additional AAA-related deaths occurred be-
tween days 31 and 365, resulting in an AAA-related 1-year
mortality of 3.4% (SE, 0.0102%; Fig 3). All-cause mortality
at 1 year was 6.7% (SE, 0.0141%, Fig 2). Secondary out-
Table IV. Adverse event categories by body system
System
Bleeding Hematoma (abdominal, sub
(intra-op, post-op, rectal)
toes, thrombocytopenia,
Cardiac MI, CHF, arrhythmias, atria
asystole, bradycardia, tach
pressure, fluid overload, t
Cancer All diagnoses of cancer: bon
Edema Upper or lower extremity ed
Gastrointestinal Nausea, vomiting, diarrhea,
adynamic ileus, cholecysti
gastroenteritis/paresis, pa
colostomy, gas pain, hiccu
cholecystectomy, sigmoid
malnutrition, weight gain
Genitourinary BPH, UTI, hernia (diaphrag
retention, urethral dilatat
Infection Sepsis, fever, elevated WBC
redness/swelling
Neurologic CVA, TIA, hemiparesis, cer
polyneuropathy, seizure,
dementia, encephalopathy
tremors
Orthopedic Bone fraction, arthritis, join
multiple trauma
Other Auto accident, cataract surg
hypocalcemia, albumin, L
headache, fatigue, hepato
incision inflammation or w
restlessness
Pulmonary/upper respiratory Pneumonia, atelectasis, pleu
COPD, bronchitis, bronc
hypoxia, infiltrate, pneum
Renal Renal insufficiency or failure
output, renal cysts, renal
Unknown Unknown cause of death
Vascular Thrombosis, embolism (inc
ischemic foot, arterial trau
laceration, carotid artery s
Wound Seroma, cellulitis, wound de
ARDS, Acute respiratory distress syndrome; BPH, benign prostatic hyper
obstructive pulmonary disease;CVA, cerebrovascular accident;DJD, degene
electrocardiogram; ENT, ear-nose-throat; LFT, liver function test; GI, g
shortness of breath; TB, tuberculosis; TIA, transient ischemic attack; URI,comes are detailed in Table II.Age, gender, and comorbidity analyses
Operative mortality (30-day). No factors were de-
termined to be associated with 30-day operative mortality
when using logistic regression. Thirty-day operative mor-
tality for womenwas 5.7% compared with 2.2% inmen (P
.18), but women were an average of 3 years older than men
(72.7  8.0 years [range, 47-86] vs 69.7  7.2 [range,
41-85 year], P  .01).
Aneurysm-related mortality. AAA-related mortality
at 1 year was predicted by female sex and history of myo-
cardial infarction (Cox proportional hazard analysis, Table
III). Women were 4.2 times more likely to suffer AAA-
related death at 1 year (9.6%) thanmen (2.2%, P .02, 95%
confidence interval [CI], 1.3%-13.9%). Patients with a his-
Definition
), hemorrhage (intra-abdominal, mucous membrane), bleeding
ulopathy, low hematocrit, post-procedure transfusion, purpura
ia
illation, cardiomyopathy, ischemia, hypertension, hypotension,
ia, ECG changes (ST depression, T-wave changes), chest pain/
nea, hypovolemia, cardiopulmonary arrest, diabetes
lon, lung, prostate, renal, sarcoma
scrotal
tipation, SBO, bowel ischemia, GI bleed, GI ulcers, dehydration,
orexia, C. Diff infection, diverticulitis, Dysphagia,
titis, gall bladder, biliary blockage, fistula, colonoscopy,
asogastric aspirate, gastric mass, colitis, colon necrosis,
tion, traumatic Foley removal, upset stomach, abdominal pain,
c, incisional, inguinal, ventral, epigastric) impotence, urinary
idney stones, foul-smelling urine
trophils, bacteremia, fungal, leukocytosis, infection, calf
infarct, depression, confusion, syncope, vertigo or dizziness,
sis, numbness, paresthesia, altered mental status, delirium,
izo-affective disorder, psychosis, numbness, mood swings,
(hip, knee), DJD, back pain, LE injury, torn rotator cuff,
kin rash, abnormal lab values (electrolyte imbalance,
etc), decubitus ulcer, tinnitus, weakness, goiter, cold symptoms,
ty, macular degeneration, ENT tumor, infiltrate swelling,
ess, multi-system organ failure, narcotic overdose, testicle pain,
fusion, SOB, respiratory failure or distress, ARDS, URI, TB,
sm, cough, decreased breath sounds, DOE, lung crepitations,
rax, nasal obstruction, sleep apnea, tracheostomy
ysis, elevated creatinine/BUN, renal bypass, decreased urine
stenosis, urosepsis
pulmonary embolism), DVT, claudication, endarterectomy,
poor CIA flow, decreased lower extremity pulses, plaque, vein
is, secondary procedure, thrombectomy
nce, abscess, drainage, non-healing, wound infection
; BUN, blood urea nitrogen; CIA, common iliac artery; COPD, chronic
joint disease;DOE, dyspnea on exertion;DVT, deep vein thrombosis; ECG,
testinal; MI, myocardial infarction; SBO, small-bowel obstruction; SOB,
respiratory infection; UTI, urinary tract infection.dural
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those without history of myocardial infarction (1.8%, 95%
CI, 1.1%-12.9%, P  .03).
All-cause mortality. Multivariate analysis showed sig-
nificant predictors of all cause-mortality at 1 year included
age, female gender, and renal failure (Table III). Because
age, as a continuous variable, was a predictor, it was also
examined categorically as age 65 years or age 65 year.
Patients 65 were 6.3 times more likely to die 1 year of
follow-up (8.3%) than patients aged 65 (1.4%, P  .04).
Table V. Early (0-30 days) and late (31-365 days) adverse
System
0-30 days (early)
% (n/N)
Patients with 1 AE 71.2 (230/323)
Bleeding 40.2 (130/323)
Cardiac 18.9 (61/323)
Cancer 1.2 (4/323)
Edema 2.8 (9/323)
Gastrointestinal 17.0 (55/323)
Genitourinary 4.6 (15/323)
Infection 12.4 (40/323)
Neurologic 7.7 (25/323)
Orthopedic 2.5 (8/323)
Pulmonary 21.7 (70/323)
Renal 5.0 (16/323)
Vascular 5.9 (19/323)
Wound 7.1 (23/323)
Othera 17.0 (55/323)
Unknown 1.5 (5/323)
Deaths 2.8 (9/323)
aThe fourth manufacturer provided the code of “Other” with no event term
following events were considered “Other,” some of which New England
drainage, anxiety, blindness, bradycardia, Candida in urine, congestive
impotence, incisional pain, oral thrush, percutaneous endoscopic gastrosto
sinus surgery, splenectomy, retrograde ejaculation, embolectomy, tracheob
Table VI. Early (0-30 days) and late (31-365 days) seriou
Category
0-30 days (early)
% (n/N)
Patients with 1 SAE 26.3 (64/243)
Bleeding 3.3 (8/243)
Cardiac 7.8 (19/243)
Cancer 1.6 (4/243)
Edema 0.0 (0/243)
Gastrointestinal 8.2 (20/243)
Genitourinary 1.2 (3/243)
Infection 1.2 (3/243)
Neurologic 1.6 (4/243)
Orthopedic 0.4 (1/243)
Pulmonary 10.7 (26/243)
Renal 3.7 (9/243)
Vascular 4.9 (12/243)
Wound 2.1 (5/243)
Othera 1.2 (3/243)
Unknown 2.1 (5/243)
Deaths 2.9 (7/243)
aSee Table V footnote for explanation.Women were 2.6 times more likely to die by the 1-yearanniversary (13.2%) than men (5.4%, P  .04). Patients
with renal failure were 6.2 times more likely to die1 year
(32.5%) than those without (5.9%, P  .01).
The relationship between gender and all-cause mortal-
ity at 1-year may be partially explained by confounding
due to age. Women in this study were on average 3 years
older (mean age, 72.7) than the men in this study (mean
age, 69.7). When adjusting for age, the relationship
between sex and all-cause mortality is no longer significant
(P  .12), but the relationship between age and all-cause
nts (AE) by body system
31-365 days (late) 0-365 days
% (n/N) % (n/N)
32.2 (101/314) 78.3 (253/323)
1.3 (4/314) 40.9 (132/323)
6.1 (19/314) 22.6 (73/323)
1.0 (3/314) 2.2 (7/323)
0.0 (0/314) 2.8 (9/323)
5.4 (17/314) 20.7 (67/323)
6.7 (21/314) 10.5 (34/323)
1.0 (3/314) 12.7 (41/323)
5.1 (16/314) 12.7 (41/323)
2.9 (9/314) 4.6 (15/323)
4.5 (14/314) 24.5 (79/323)
0.3 (1/314) 5.0 (16/323)
1.9 (6/314) 7.4 (24/323)
1.6 (5/314) 8.7 (28/323)
8.9 (28/314) 22.0 (71/323)
2.5 (8/314) 4.0 (13/323)
3.8 (12/314) 6.5 (21/323)
rding to the summary of safety and effectiveness for that manufacturer, the
rch Institutes Inc would have classified into different categories: wound
failure exacerbation, elevated liver function tests, hyperkeratotic wound,
be placement, pleural effusion, positive blood culture, respiratory distress,
itis, tracheostomy, winged scapula, yeast in the urinary tract.
erse events (SAE) by body system
31-365 days (late) 0-365 days
% (n/N) % (n/N)
15.3 (36/236) 35.8 (87/243)
0.4 (1/236) 3.7 (9/243)
3.4 (8/236) 11.1 (27/243)
1.3 (3/236) 2.9 (7/243)
0.0 (0/236) 0.0 (0/243)
2.5 (6/236) 10.3 (25/243)
1.7 (4/236) 2.9 (7/243)
0.4 (1/236) 1.6 (4/243)
1.7 (4/236) 3.3 (8/243)
0.4 (1/236) 0.8 (2/243)
2.5 (6/236) 12.3 (30/243)
0.0 (0/236) 3.7 (9/243)
0.8 (2/236) 9.9 (24/243)
0.0 (0/236) 2.1 (5/243)
1.3 (3/236) 2.5 (6/243)
3.4 (8/236) 5.3 (13/243)
4.7 (11/236) 7.4 (18/243)eve
. Acco
Resea
heart
my tus advmortality does remain significant (P  .01). Because
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explained by the age differences between men and
women, gender was dropped as a predictive variable in
backwards elimination.
Aneurysm size analysis. The average preoperative an-
eurysm size was 5.9 cm (range, 3.1-10.0 cm). Small aneu-
rysms (5.5 cm) comprised 43.2% of the cohort (n 126);
however, aneurysm size did not have an effect on operative
mortality (30 day) or survival at 12 months.
Adverse events. The categorization of adverse events
is defined in Table IV. The overall adverse event rate was
71% in the perioperative period and 78% at 1 year (Table
V). Bleeding (41%), pulmonary (24%), cardiac (23%), and
gastrointestinal (21%) events were the most common. Se-
rious adverse events occurred in 26% perioperatively and in
36% at 1 year (Table VI). Most of the serious events were
pulmonary (12%) and cardiac (11%). At 30 days, 74% of the
patients were free from serious morbidity, and 64% re-
mained free from serious morbidity at 1 year (Fig 4). Major
adverse events occurred in 11% perioperatively and in 15%
at 1 year (Table VII). Most of the MAEs were due to death
(6%) and myocardial infarction (6%). At 30 days, 89% were
free from MAEs, and 84% remained free from MAEs at 1
year (Fig 5).
DISCUSSION
This aggregate data set represents a contemporary
group of patients treated with open surgery for infrarenal
aortic aneurysms at institutions participating in IDE clinical
endograft trials. Patients were enrolled prospectively, and
follow-up was carefully monitored with comprehensive ad-
judication of events. Although the four trials enrolled dif-
ferent numbers of patients, and they differed to some
extent in inclusion and exclusion criteria, definitions, and
end points, it was determined that the data were poolable.
Specific differences noted between the trials included the
incidence of hypertension, smoking, cardiac arrhythmias,
Fig 4. Freedom from serious adverse events.and aneurysm size.AAA size variation was likely related to the 2002 pub-
lication of the prospective randomized trial of immediate
open surgical repair vs closely monitored watchful waiting
for AAAs 5.5 cm diameter. That study failed to demon-
strate a survival benefit for immediate open surgical repair,
and recruitment for the ongoing and subsequent EVAR
trials was likely shifted towards larger diameter AAAs after
its release.13 Our analysis failed to demonstrate a difference
in operative mortality between large and small AAAs, with
rates of 3.6% and 2.4%, respectively (P  .54).
Operative mortality for men and women undergoing
elective open surgical repair has been reported in popula-
tion-based reports to be 3.5% to 4.6%, whereas the mortal-
ity rate in these four pooled studies was 2.8%.14-18 All
would concur that the results in this series are concordant,
if not better, possibly because all the published literature
was from medical centers, whereas this surgical control
aggregate is derived from centers of excellence selected by
manufacturers. The same observation can be made for
1-year survival.
Comparison of operative mortality for open surgical
repair in women compared with men remains complex.
Most reports suggest a higher operative mortality rate for
women undergoing open repair, but low numbers of
women and age at time of surgery confound the analyses.18
In our report, perioperative mortality was 2.6-fold greater
in women (P  .18), but on average, the women were 3
years older. At 1 year, the all-cause mortality ratio was the
same in women vs men, at 2.6, but with age-adjustment,
the difference between genders was no longer significant
(P  .12). The limited data available on women remain a
weakness in all aneurysm trials. For example, the Aneurysm
Detection andManagement (ADAM) trial had1% female
enrollment.13 Our data set includes only 54 women
(16.7%), and it should be pointed out that none of the
individual IDE trials was adequately powered to determine
the effect of gender on survival.
Validity of pooling. Statistically significant differ-
ences were found across manufacturers of baseline charac-
teristics for arrhythmia (P  .01), peripheral vascular dis-
ease (P .03), hypertension (P .01), smoking (P .01)
and preoperative aneurysm diameter size (P  .01). How-
ever, these baseline differences did not appear to have an
effect on the primary end points of interest, even when
adjusting for manufacturer. Thus, the data are sufficiently
homogenous to be statistically poolable. It is recom-
mended, however, that all future studies using the SVS
surgical control data set include these variables as potential
covariates as a precaution. Further, it is believed that the
high statistical power and precision resulting from the
combination of these individually collected data sets will far
outweigh the differences among the patient populations of
these studies.
A limitation of the SVS surgical control data set, with
respect to serious adverse events classification, is the lack of
pertinent information available in some data sets, such as
hospitalization status and limited text or narrative informa-
tion for proper serious adverse events coding. Nonetheless,
JOURNAL OF VASCULAR SURGERY
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follow-up far outweigh the differences among the IDE
trials. This allowed meaningful data pooling, reflecting the
overall results of open repair rather than the outcomes of
any specific device. Statistical analysis of the data ensures
that the patients are poolable. All of the trials have been
previously published, along with publications that have
compared differing devices.4-7,15
CONCLUSIONS
In summary, the potential justification for using
pooled, historical, open surgical control data includes the
fact that open surgical control patients are likely to become
less common overall and increasingly dissimilar in anatomic
and physiologic comorbidities compared with the typical
patient treated with EVAR. The detailed outcomes in this
tightly controlled, highly audited group of patients are as
good as—and possibly better than—those reported in con-
temporary population-based reports. Assuming that open
surgical controls will be requested by the FDA and other
regulatory bodies as new EVAR devices are developed, the
clinical disparity, recruiting difficulty, and significant ex-
pense associated with the open surgical controls might be
Fig 5. Freedom from major adverse events.
Table VII. Early (0-30 days) and late (31-365 days) majo
System
0-30 days (early)
% (n/N)
Patients with 1 MAE 11.1 (36/323)
Death 2.8 (9/323)
Myocardial infarction 4.0 (13/323)
Cerebrovascular accident 1.5 (5/323)
Renal failure 2.5 (8/323)
Respiratory failure 4.3 (14/323)
Paralysis/paraparesis 0.3 (1/323)
Bowel ischemia 6.2 (2/323)avoided by using this pooled data set.Open surgical repair of abdominal aortic aneurysms is
safe and effective in preventing aneurysm rupture and
avoiding AAA-related death. These detail-rich, highly au-
dited data may potentially serve as a benchmark in future
assessments of endovascular AAA repair devices.
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